OR WAIT null SECS
February 06, 2024
The addition of another amino acid recognizer as well as improvements in surface chemistry, reagents, and software expand the proteome coverage of Quantum-Si’s Platinum sequencing platform.
February 05, 2024
The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe.
Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.
February 02, 2024
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
January 24, 2024
Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.
January 22, 2024
Abzena has launched its AbZelect platforms, designed for improving cell line development.
January 18, 2024
The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
January 17, 2024
Charles River’s off-the-shelf rep/cap plasmids are intended to simplify gene therapy supply chains.
The acquisition marks a pivotal expansion for the company into the US market.
January 11, 2024
Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.